Tag: Ofev

In clinical trials like INPULSIS and INBUILD, over 60% of patients taking nintedanib reported experiencing diarrhea, making it the most common adverse event associated with the medication [1.2.1, 1.8.5]. The question is not just *if*, but how to manage when it occurs. So, **can nintedanib cause diarrhea?** The answer is a definitive yes.

OFEV (nintedanib), first approved by the FDA in 2014 for idiopathic pulmonary fibrosis (IPF), is an antifibrotic medication that has since gained additional indications. This therapy is designed to slow the progression of various interstitial lung diseases by targeting specific signaling pathways involved in the formation of scar tissue.

In clinical studies, Ofev (nintedanib) has been shown to slow the rate of lung function decline by approximately 50% in people with idiopathic pulmonary fibrosis (IPF) compared to those not on the medication. Understanding how do you know if Ofev is working involves tracking a combination of objective clinical markers and patient-reported outcomes over time.

Affecting approximately 140,000 Americans, Idiopathic Pulmonary Fibrosis (IPF) is a serious lung condition [1.4.1]. A key question for patients is: **Is Esbriet being discontinued?** While the brand-name drug remains available, the treatment landscape has significantly changed with the introduction of generic pirfenidone [1.3.1, 1.4.3].

In the United States, idiopathic pulmonary fibrosis (IPF) affects an estimated 100,000 people, with 30,000 to 40,000 new cases diagnosed annually. This article explores a key treatment: **what is the drug Esbriet used for?**